<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Leukemia</journal-id><journal-id journal-id-type="iso-abbrev">Leukemia</journal-id><journal-title-group><journal-title>Leukemia</journal-title></journal-title-group><issn pub-type="ppub">0887-6924</issn><issn pub-type="epub">1476-5551</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22430636</article-id><article-id pub-id-type="pmc">3460214</article-id><article-id pub-id-type="pii">leu201275</article-id><article-id pub-id-type="doi">10.1038/leu.2012.75</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3<sup>&#x0002b;</sup> regulatory T cells</article-title><alt-title alt-title-type="running">Letter to the Editor</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coles</surname><given-names>S J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hills</surname><given-names>R K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>E C Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Burnett</surname><given-names>A K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Man</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="note1"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Darley</surname><given-names>R L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tonks</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>3</sup></xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><sup>1</sup><institution>Department of Haematology, Institute of Cancer and Genetics, Cardiff University</institution>, Wales, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Institute of Infection and Immunity, School of Medicine, Cardiff University</institution>, Wales, <country>UK</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>Tonksa@cf.ac.uk</email></corresp><fn fn-type="present-address" id="note1"><label>3</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>09</month><year>2012</year></pub-date><pub-date pub-type="epreprint"><day>20</day><month>03</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>13</day><month>04</month><year>2012</year></pub-date><volume>26</volume><issue>9</issue><fpage>2146</fpage><lpage>2148</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 Macmillan Publishers Limited</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link></license-p></license></permissions></article-meta></front><body><p>CD200 is a type-1a transmembrane cell-surface glycoprotein that is normally expressed in critical tissues such as the central nervous system and testis, as well as certain leukocytes, including T and B lymphocytes, where its role is to promote peripheral tolerance and protect immune privileged sites.<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> CD200 has no known intracellular signaling motif, but induces immunosuppression through engagement with CD200R, a cell-surface receptor homolog, which is expressed on leukocytes of myeloid lineage, including mast-cells, macrophages, basophils, dendritic cells as well as certain T-cell populations.<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> CD200, which is frequently overexpressed in acute myeloid leukemia (AML) patient blasts and associated with a worse outcome,<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> has the potential to induce the formation of CD4<sup>&#x0002b;</sup>CD25<sup>&#x0002b;&#x0002b;</sup>FoxP3<sup>&#x0002b;</sup> regulatory T cells (Tregs),<sup><xref ref-type="bibr" rid="bib4">4</xref></sup> a subset of immunosuppressive T cells that are linked with a poor prognosis in AML.<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> Most importantly, Tregs have been documented to suppress the anti-leukemia response <italic>in vitro</italic> from AML patients,<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> suggesting that these cells have an important role in regulating AML patient tumor immunity. We therefore investigated whether CD200 protein expression on human AML blasts was associated with an increased frequency of Treg cells in AML using a cohort of 40 AML patients (at the point of diagnosis before to any treatment; <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref> for patient demographic). AML blast CD200 protein expression and patient Treg frequency was analyzed by flow cytometry (for full gating strategy, refer to <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>). The data show that CD200 blast expression level correlated significantly with the frequency of Treg cells (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). This association was found to be independent of white blood cell count (<xref ref-type="fig" rid="fig1">Figure 1b</xref>), suggesting that CD200 expression on AML blasts promotes Treg formation. We also examined whether CD200 expression was differentially expressed on AML blasts with a putative leukemic stem cell phenotype (CD34<sup>&#x0002b;</sup>CD38<sup>&#x02212;</sup>),<sup><xref ref-type="bibr" rid="bib7">7</xref></sup> but could find no evidence for this within the six samples examined (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>).</p><p>Given that the depletion of Tregs has been shown to improve T-cell-mediated therapy, as well as improving antitumor activity in leukemia patients that are in complete remission;<sup><xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib9">9</xref></sup> we investigated whether Tregs from CD200<sup>hi</sup> patients were functionally immunosuppressive. We examined the ability of purified Tregs to suppress na&#x000ef;ve responder T-cell (CD4<sup>&#x0002b;</sup>CD25<sup>&#x02212;</sup>) proliferation following CD3/CD28 co-stimulation (refer to <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials and Methods</xref>). The data demonstrate that Tregs isolated from CD200<sup>hi</sup> AML patients were capable of suppressing T-cell proliferation at responder to Treg ratios of &#x0003e;1 to 0.01 (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Reciprocal analysis of Tregs from CD200<sup>lo</sup> patients could not be carried out because of the extremely low frequencies of these cells in CD200<sup>lo</sup> patients (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). In fact, Treg frequencies in CD200<sup>lo</sup> AML patients were uniformly lower than in healthy donor controls, suggesting that CD200 has an influence on Treg induction in this context.</p><p>Since mouse models have suggested that CD200-induced Tregs are likely to mediate Th1 immunosuppression,<sup><xref ref-type="bibr" rid="bib10">10</xref></sup> a cytokine response with a prognostic link in leukemia,<sup><xref ref-type="bibr" rid="bib11">11</xref></sup> we measured the Th1 cytokine response (TNF&#x003b1;, IL2 and IFN&#x003b3; production) in CD200<sup>hi</sup> patients before and after Treg depletion. Representative flow cytometric plots confirmed Treg depletion using magnetic separation (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). However, removal of Tregs alone was insufficient to significantly improve the Th1 cytokine response as detected by intracellular cytokine staining (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). Elsewhere we report that, in addition to its known influence on Treg production, CD200 is also directly immunosuppressive through engagement with CD200R on T cells in AML.<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> However, in the present study we show that removal of Treg cells alone is unlikely to show effect in these assays when large numbers of CD200<sup>&#x0002b;</sup> blast cells are present. These data would predict that Tregs have little impact on immunosuppression at diagnosis when the disease burden is high, as the dominant mode of T-cell suppression would be mediated by CD200<sup>hi</sup> blasts directly inhibiting Th1 responses.<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> Conversely, following chemotherapy, the reduction of tumor burden would be predicted to make Treg-mediated immunosuppression cells the dominant factor.</p><p>In summary, these findings illustrate a clear correlation between blast CD200 expression level and the frequency of immunosuppressive Treg cells. Previous studies of human AML have also reported increased frequencies of Tregs in untreated disease<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> as well as during regeneration following treatment,<sup><xref ref-type="bibr" rid="bib14">14</xref></sup> however, the link with CD200 expression has not previously been established. Our data also indicate that while Tregs in these patients may be functionally immunosuppressive, they may only become influential following cytoreduction. Indeed, several studies have identified that increased frequencies of Tregs are associated with relapse in myeloid malignancy.<sup><xref ref-type="bibr" rid="bib15">15</xref>, <xref ref-type="bibr" rid="bib16">16</xref></sup> Furthermore, phase-I studies using anti-CD200 monoclonal antibody immunotherapy have shown that blocking CD200 is sufficient to reduce the Treg frequency in chronic lymphocytic leukemia patients,<sup><xref ref-type="bibr" rid="bib17">17</xref></sup> illustrating that blocking CD200 may be therapeutically advantageous in AML.</p></body><back><ack><p>This work was funded by Leukemia and Lymphoma Research UK. We thank Gareth Betts (Cardiff University) for his technical assistance in analyzing Tregs. We are grateful to the patients for access to material enrolled in the NCRI clinical trials. Dr Steve Coles is currently funded by NISCHR, Wales, UK.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on the Leukemia website (http://www.nature.com/leu)</p></fn><fn><p><bold>Author Contributions</bold></p><p>SJC designed and performed the experiments/analyzed all data and co-wrote the manuscript. RKH provided statistical guidance. ECYW provided biological insight. AKB provided resources and clinical insight. SM, RLD and AT contributed to experimental design and co-wrote the manuscript.</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>GJ</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Puklavec</surname><given-names>MJ</given-names></name><name><surname>Brown</surname><given-names>MH</given-names></name><name><surname>Barclay</surname><given-names>AN</given-names></name></person-group><article-title>The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans</article-title><source>Immunology</source><year>2001</year><volume>102</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">11260322</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>GJ</given-names></name><name><surname>Cherwinski</surname><given-names>H</given-names></name><name><surname>Foster-Cuevas</surname><given-names>M</given-names></name><name><surname>Brooke</surname><given-names>G</given-names></name><name><surname>Puklavec</surname><given-names>MJ</given-names></name><name><surname>Bigler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization of the CD200 receptor family in mice and humans and their interactions with CD200</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>3034</fpage><lpage>3046</lpage><pub-id pub-id-type="pmid">12960329</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonks</surname><given-names>A</given-names></name><name><surname>Hills</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Rosie</surname><given-names>B</given-names></name><name><surname>Mills</surname><given-names>KI</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><etal/></person-group><article-title>CD200 as a prognostic factor in acute myeloid leukaemia</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>566</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">17252007</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorczynski</surname><given-names>RM</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Boudakov</surname><given-names>I</given-names></name></person-group><article-title>Augmented induction of CD4&#x0002b;CD25&#x0002b; Treg using monoclonal antibodies to CD200R</article-title><source>Transplantation</source><year>2005</year><volume>79</volume><fpage>488</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">15729177</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shenghui</surname><given-names>Z</given-names></name><name><surname>Yixiang</surname><given-names>H</given-names></name><name><surname>Jianbo</surname><given-names>W</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Laixi</surname><given-names>B</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Elevated frequencies of CD4(&#x0002b;)CD25(&#x0002b;)CD127(lo) regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia</article-title><source>Int J Cancer</source><year>2010</year><volume>129</volume><fpage>1373</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">21105040</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curti</surname><given-names>A</given-names></name><name><surname>Trabanelli</surname><given-names>S</given-names></name><name><surname>Onofri</surname><given-names>C</given-names></name><name><surname>Aluigi</surname><given-names>M</given-names></name><name><surname>Salvestrini</surname><given-names>V</given-names></name><name><surname>Ocadlikova</surname><given-names>D</given-names></name><etal/></person-group><article-title>Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells</article-title><source>Haematologica</source><year>2010</year><volume>95</volume><fpage>2022</fpage><lpage>2030</lpage><pub-id pub-id-type="pmid">20801903</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Dick</surname><given-names>JE</given-names></name></person-group><article-title>Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">9212098</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Bucher</surname><given-names>C</given-names></name><name><surname>Munger</surname><given-names>ME</given-names></name><name><surname>Highfill</surname><given-names>SL</given-names></name><name><surname>Tolar</surname><given-names>J</given-names></name><name><surname>Munn</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>3793</fpage><lpage>3802</lpage><pub-id pub-id-type="pmid">19724059</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maury</surname><given-names>S</given-names></name><name><surname>Lemoine</surname><given-names>FM</given-names></name><name><surname>Hicheri</surname><given-names>Y</given-names></name><name><surname>Rosenzwajg</surname><given-names>M</given-names></name><name><surname>Badoual</surname><given-names>C</given-names></name><name><surname>Cherai</surname><given-names>M</given-names></name><etal/></person-group><article-title>CD4&#x0002b;CD25&#x0002b; regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation</article-title><source>Sci Transl Med</source><year>2010</year><volume>2</volume><fpage>41ra52</fpage></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorczynski</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Kai</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Ramakrishna</surname><given-names>V</given-names></name><etal/></person-group><article-title>Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">9916698</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego</surname><given-names>A</given-names></name><name><surname>Vargas</surname><given-names>JA</given-names></name><name><surname>Castejon</surname><given-names>R</given-names></name><name><surname>Citores</surname><given-names>MJ</given-names></name><name><surname>Romero</surname><given-names>Y</given-names></name><name><surname>Millan</surname><given-names>I</given-names></name><etal/></person-group><article-title>Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL</article-title><source>Cytometry B Clin Cytom</source><year>2003</year><volume>56</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">14582134</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coles</surname><given-names>SJ</given-names></name><name><surname>Hills</surname><given-names>RK</given-names></name><name><surname>Wang</surname><given-names>ECY</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Man</surname><given-names>S</given-names></name><name><surname>Darley</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Expression of CD200 on AML blasts directly suppresses memory T-cell function</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>2148</fpage><lpage>2151</lpage><pub-id pub-id-type="pmid">22430635</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szczepanski</surname><given-names>MJ</given-names></name><name><surname>Szajnik</surname><given-names>M</given-names></name><name><surname>Czystowska</surname><given-names>M</given-names></name><name><surname>Mandapathil</surname><given-names>M</given-names></name><name><surname>Strauss</surname><given-names>L</given-names></name><name><surname>Welsh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>3325</fpage><lpage>3332</lpage><pub-id pub-id-type="pmid">19417016</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ersvaer</surname><given-names>E</given-names></name><name><surname>Liseth</surname><given-names>K</given-names></name><name><surname>Skavland</surname><given-names>J</given-names></name><name><surname>Gjertsen</surname><given-names>BT</given-names></name><name><surname>Bruserud</surname><given-names>O</given-names></name></person-group><article-title>Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells</article-title><source>BMC Immunol</source><year>2010</year><volume>11</volume><fpage>38</fpage><pub-id pub-id-type="pmid">20618967</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delluc</surname><given-names>S</given-names></name><name><surname>Hachem</surname><given-names>P</given-names></name><name><surname>Rusakiewicz</surname><given-names>S</given-names></name><name><surname>Gaston</surname><given-names>A</given-names></name><name><surname>Marchiol-Fournigault</surname><given-names>C</given-names></name><name><surname>Tourneur</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>1669</fpage><lpage>1677</lpage><pub-id pub-id-type="pmid">19225777</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadal</surname><given-names>E</given-names></name><name><surname>Garin</surname><given-names>M</given-names></name><name><surname>Kaeda</surname><given-names>J</given-names></name><name><surname>Apperley</surname><given-names>J</given-names></name><name><surname>Lechler</surname><given-names>R</given-names></name><name><surname>Dazzi</surname><given-names>F</given-names></name></person-group><article-title>Increased frequencies of CD4(&#x0002b;)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>472</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">17215853</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mahadevan</surname><given-names>D</given-names></name><name><surname>Lanasa</surname><given-names>MC</given-names></name><name><surname>Whelden</surname><given-names>M</given-names></name><name><surname>Faas</surname><given-names>SJ</given-names></name><name><surname>Ulery</surname><given-names>TL</given-names></name><name><surname>Kukreja</surname><given-names>A</given-names></name><etal/></person-group><article-title>First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)</article-title><source>52nd ASH Annu Meet Exposition. 2465</source><publisher-name>Orlando, FL</publisher-name><year>2012</year></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Figure S1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="msword" xlink:href="leu201275x1.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob2"><label>Supplementary Figure S2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="msword" xlink:href="leu201275x2.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob3"><label>Supplementary Table S1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="msword" xlink:href="leu201275x3.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob4"><label>Supplementary Materials anf Methods</label><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="msword" xlink:href="leu201275x4.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Assessment of AML blast CD200 expression with respect to Treg frequency and function. Treg cells from 40 AML patients at diagnosis were identified by flow cytometry based on the frequency of CD3<sup>&#x0002b;</sup>CD4<sup>&#x0002b;</sup>CD25<sup>&#x0002b;&#x0002b;</sup> T cells that were &#x0003e;95&#x00025; FoxP3<sup>&#x0002b;</sup> (refer to <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>). (<bold>a</bold>) Linear regression analysis comparing AML blast CD200 expression level with the frequency of Tregs from 40 diagnostic AML samples. (<bold>b</bold>) Correlation of AML blast frequency with Treg cell frequency. To assess the suppressive function, Tregs and na&#x000ef;ve T cells (CD4<sup>&#x0002b;</sup>CD25<sup>&#x02212;</sup>) were isolated from CD200<sup>hi</sup> AML patients by magnetic separation and added together at increasing ratios before CD3/CD28 co-stimulation. Suppression was measured by the ability of Tregs to inhibit na&#x000ef;ve CD4<sup>&#x0002b;</sup> T-cell proliferation (refer to <xref ref-type="supplementary-material" rid="sup1">Supplementary Materials and Methods</xref>). (<bold>c</bold>) Suppression of na&#x000ef;ve CD4<sup>&#x0002b;</sup> T-cell proliferation by AML Treg cells at indicated Treg to responder ratios (data represent mean&#x000b1;1 s.d., <italic>n</italic>=4). (<bold>d</bold>) Treg cell frequency stratified with respect to AML blast CD200 expression. &#x0002a;<italic>P</italic>&#x0003c;0.05 and &#x0002a;&#x0002a;<italic>P</italic>&#x0003c;0.01 analyzed by one-way analysis of variance with Tukey's multiple comparison test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leu201275f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Assessment of AML patient Treg depletion in recovering the Th1 response in CD200<sup>hi</sup> patients. Tregs cells were depleted from CD200<sup>hi</sup> AML patients by magnetic separation. (<bold>a</bold>) Representative flow cytometric data depicting T cells (i) before depletion of Tregs (CD3<sup>&#x0002b;</sup>CD4<sup>&#x0002b;</sup>CD25<sup>&#x0002b;&#x0002b;</sup>FoxP3<sup>&#x0002b;</sup>) and (ii) following Treg depletion from a CD200<sup>hi</sup> AML patient. AML cells were stimulated with PMA/ionomycin for 6&#x02009;h at 37&#x02009;&#x000b0;C before intracellular Th1 cytokine staining was performed. Flow cytometry was used to assess Th1 cytokine levels within the CD45<sup>&#x0002b;&#x0002b;</sup>CD3<sup>&#x0002b;</sup>CD4<sup>&#x0002b;</sup> fraction. (<bold>b</bold>) Summary data showing the Th1 response from CD200<sup>hi</sup> AML patients&#x000b1;Treg cells (<italic>n</italic>=6).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leu201275f2"/></fig></floats-group></article>